Molecular profi ling has resulted in the classifi cation of breast cancer into six distinct subtypes [1, 2] that have diff erential prognoses and optimal treatment regimes. Th e subgroups with the best prognosis are the luminal A and luminal B groups, which are distinguished by their expression of oestrogen receptor (ER) alpha. Luminal A and luminal B are the most commonly diagnosed types, comprising 70% of breast tumours. Correspondingly, the most widely used treatment for breast cancers is antioestrogen therapy, which is very eff ective for patients with ER + tumours.
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Personalised therapy for breast cancer is a current goal, and characterisation of breast tumour biopsies into particular molecular subtypes with predicable outcomes is essential to achieve this goal. Th is characterisation requires a better understanding of the signature genes in these sub type profi les and the molecular mechanisms by which they are determined. Th is will provide insights into tumour initiation and progression and will better guide treatment strategies. Furthermore, many breast tumours recur and about 30% of patients develop resistance to anti-oestrogen therapy. Th e mechanism for this resistance is not clear and is currently an important area of research.
Th e transcriptional regulator E74-like factor 5 (Elf5) has previously been associated with regulation of placenta tion [3] and alveologenesis, the process by which the mammary gland develops milk-producing acinar structures during pregnancy [4, 5] . In a manuscript from Chris Ormandy's laboratory, published recently in PLoS Biology [6] , the authors hypothesised that Elf5 -which is expressed primarily in the ERprogenitor cells in the mouse mammary gland -could have a role in determining the diff erent subtypes of breast cancer. Firstly, they examined Elf5 expression in published datasets and found that expression was highest in the basal and normal-like subtypes and also in normal breast, while expression was low in all other subtypes. Using inducible expression of Elf5 in the ER + luminal breast cancer cell lines T47D and MCF7, Elf5 binding sites were determined by chromatin immunoprecipi ta tion-sequencing analysis. Th is analysis identifi ed 164 target genes including forkhead box protein A1 (FOXA1), RUNX1 and GATA3. Additionally, a panel of mitogenic genes were shown to be repressed by Elf5. Th is 164-gene signature accurately predicts ER status, suggesting that the poorer prognosis of ERtumours could be due to Elf5-regulated genes. Importantly, forced Elf5 expression suppresses oestrogen sensitivity indirectly and, while oestrogen can reduce Elf5 expression, this was blunted in tamoxifen-resistant cells. Th e most striking outcome of this work is that Elf5 can alter the molecular subtype as luminal cells become either basal and Her2 + (MCF7) or normal-like and claudin-low (T47D), while HCC1937 basal cells become normal-like and claudin-low.
Th is manuscript is a gene expression analysis tour de force. Consequently, there is a substantial amount of data to be digested that will be appreciated particularly by the conoscenti. However, the signifi cance of the paper can be distilled into two main observations. Firstly, the level of Elf5 expression can change the molecular subtype of breast cancer cell lines implicating Elf5 as a critical regulator of subtype. Secondly, Elf5 is a marker of ERcells, suppresses oestrogen activity in luminal cells and overrides the anti-proliferative eff ects of anti-oestrogens, possibly promoting resistance. Th ese are interesting and important discoveries and raise the possibility that expres sion of Elf5 could be a marker of future antioestrogen therapy failure in ER + tumours.
Abstract
A variety of transcription factors has been shown to regulate lineage commitment in the mammary gland and to be associated with diff erent molecular subtypes of breast cancer. E74-like factor 5 (Elf5) has now been identifi ed as a marker of oestrogen receptor status, and high expression correlates with more aggressive basal cancers and resistance to anti-oestrogens. Manipulation of Elf5 transcript levels perturbs the molecular profi les of luminal and basal subtypes, highlighting the possibility that targeting Elf5 could provide a new approach for the treatment of basal cancers.
A number of challenging questions arise from this work. Firstly, there is a major diff erence in terms of molecular signature between the response of T47D and MCF7 cells (both luminal ER + ) to forced Elf5 expression. Will every ER + luminal breast cancer cell line behave diff erently to Elf5 overexpression and how can we extrapolate these fi ndings to real ER + tumours? Clearly, cell-specifi c and subtype-specifi c factors interact with Elf5. What are these interacting factors? FOXA1 has recently been shown to have a similar role to Elf5 in that it can regulate luminal and basal cell plasticity -knockdown of FOXA1 in luminal breast cancer cells results in a basal molecular signature [7] . Since Elf5 regulates FOXA1, which in turn regulates expression of ERα [8] , there could be antago nism between Elf5 and FOXA1 for binding to the ERα promoter. Th is interaction is further complicated by the role of GATA3, which is a marker of the luminal subtypes and is shown in this study to be regulated by Elf5, although it is not a FOXA1 target [8] .
Perhaps curious is that the expression of Elf5 is similar in the cancer subtype with the worst prognosis (basal) to that in normal breast. Th is brings us to the normal developmental role of Elf5 where overexpression in virgin animals induces precocious alveologenesis [9] . Th e authors suggest that Elf5 establishes the secretory alveolar cell lineage and that Elf5 and FOXA1 provide the key to progenitor cell fate decisions. Recent genetic studies demonstrated that the balance of the ER + /Gata3 and ER -/pStat5 lineages is determined by the trans criptional repressor Zfp157 [10] . Th e relationship between Elf5 and Zfp157 has not been determined but raises the question of how expression of Elf5 is regulated. Th e chromatin immunoprecipitation-sequencing analysis pulled out Stat binding motifs, and Stat5 has been suggested to be a regulator of Elf5 expression [11] . Is there a positive regulatory loop between Stat5 and Elf5 and/or competition between Elf5 and Stat5 for target genes?
We are now beginning to understand the mechanisms that regulate the transcriptional profi les of breast cancer subtypes. Th is should result in better prognostic analyses and the design of targeted therapies for basal and antioestrogen-resistant breast cancers.
